physostigmine/oksendamine

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 48 tulemused

A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE A multicenter trial to evaluate the efficacy of controlled-release physostigmine salicylate, a cholinesterase inhibitor, was conducted in 1,111 mild-to-moderate Alzheimer's disease (AD) subjects. METHODS During dose titration, subjects received 18, 24, or 30 mg of physostigmine or placebo

A Comparison of Resource Utilization in the Management of Anticholinergic Delirium Between Physostigmine and Nonantidote Therapy.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Background: Antimuscarinic delirium is associated with significant morbidity, and its management requires substantial resource allocation, including intubation, restraint, and intensive care unit (ICU) placement. There is controversy over the management of these patients. Physostigmine can

Reversal of sedation and respiratory depression after anaesthesia by the combined use of physostigmine and naloxone in neurosurgical patients.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

A clinical trial of the combination of naloxone in a low dose (1-1.5 micrograms X kg-1 body weight) with physostigmine (0.5-1.0 mg i.v.) was made to elucidate whether this combination could reverse postanaesthetic overdosing in neurosurgical patients without increasing postoperative pain. The

Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Recently, new drugs and techniques for the treatment of postoperative pain were introduced, with the goal of enhancing opiates' analgesia while minimizing their side-effects. Cholinergic agents play an antinociceptive role, but their clinical use is quite limited, due to side-effects.

Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Physostigmine salicylate (2.0 mg) or 0.9% NaCl (2.0 ml) was administered intravenously in a double-blind fashion to adult volunteers in an attempt to reverse the effects of a 0.05-mg/kg dose of lorazepam given intravenously 30 min earlier. No other medication affecting the central nervous system was

Rectal methohexitone induction in pediatric outpatients: physostigmine does not enhance recovery.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Rectal methohexitone (25 mg X kg-1) was used to induce anaesthesia in 15 unpremedicated children scheduled to undergo bilateral myringotomies as outpatients. Induction time ranged from 4 to 11 minutes. In the recovery room, all children received a slow intravenous injection of physostigmine (60

Physostigmine for the prevention of postanaesthetic shivering following general anaesthesia - a placebo-controlled comparison with nefopam.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Physostigmine was studied for its efficacy in the prevention of postanaesthetic shivering compared to nefopam and placebo. We studied 89 patients undergoing abdominal and urological surgery. The study was randomised and double-blind, the patients received physostigmine 2 mg (n = 31), nefopam 10 mg

[Ketamine racemate versus S-(+)-ketamine with or without antagonism with physostigmine. A quantitative EEG study on volunteers].

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The potency of S-(+)-ketamine is approximately double that of the racemic ketamine. This study was carried out to investigate the recovery of cerebral electrical function after a bolus of 1.3 mg/kg ketamine or 0.65 mg/kg S-(+)-ketamine and subsequent continuous application of 4 mg/kg h ketamine per

Anesthesia with 1.5 minimum alveolar concentration sevoflurane is not altered by physostigmine as measured by bispectral and clinical indices.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE To evaluate the effect of physostigmine on 1.5% sevoflurane anesthesia and recovery. METHODS Prospective, randomized, double-blinded study. METHODS Operating room of a university-affiliated, metropolitan hospital (Aretaieion Hospital and St Savas Hospital). METHODS Forty female American

A model for carbamate and organophosphate-induced emesis in humans.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

In human volunteers, studies to assess the adverse effects of the carbamate anticholinesterase physostigmine showed that the intramuscular dose observed to induce emesis in 50% of subjects tested (ED50) was 28.1 (23.5-120.7) micrograms/kg. This dose reduced whole blood cholinesterase (ChE) activity

Physostigmine reversal of drug-induced paradoxical excitement.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Paradoxical excitement associated with intravenous conscious-sedation in a patient undergoing dental surgery was successfully reversed with 1.0 mg physostigmine. Physostigmine is felt to have exerted this effect by 2 mechanisms: the re-establishment of homeostasis in the CNS via augmented

Protection by a transdermal patch containing physostigmine and procyclidine of soman poisoning in dogs.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The prophylactic efficacy of a combinational patch system containing physostigmine and procyclidine against soman intoxication was evaluated using dogs. Female beagle dogs (body weights 9-10 kg) were shaved on the abdominal side, attached with a matrix-type patch (7x7 cm) containing 1.5% of

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND The efficacy of extended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 subjects with mild-to-moderate Alzheimer disease (AD) in a multicenter trial. METHODS Subjects initially entered a dose-enrichment phase in which they received 1 week each of

Do patients profit from physostigmine in recovery from desflurane anaesthesia?

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Physostigmine is the drug of choice in the central anticholinergic syndrome, but has also been used in post-operative mental derangement secondary to sedatives and volatile anaesthetics. The aim of this double-blind, randomized, prospective study was to determine whether physostigmine

Physostigmine and anaesthesia emergence delirium in preschool children: a randomized blinded trial.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND A significant proportion of preschool children experiences severe emergence agitation after anaesthesia. The symptoms of disorientation, restlessness, inconsolable crying and thrashing resemble an acute psychosis similar to an agitated central anticholinergic syndrome. The primary aim of

Eelmine
1
2
3
4
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel